Nurix Therapeutics is a clinical-stage biopharmaceutical company developing small molecule and antibody treatments targeting cancer, inflammatory diseases, and other conditions. The company's pipeline includes multiple oral drug candidates in clinical trials, such as BTK degraders for B-cell malignancies and autoimmune disorders, a CBL-B inhibitor for immuno-oncology, and an IRAK4 degrader for rheumatoid arthritis and related inflammatory diseases. The company has established partnerships with Gilead Sciences, Sanofi, and Pfizer for joint development and commercialization of several drug programs.
1Y: 25.50 (+184.3%) · range 8.24–27.79
entry readiness 16 · NOT READY · exit proximity 15
Value area 14.24–23.47 · 14% of 120d volume overhead · clean runway
No source detections in the last 21 days.
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +2.15% | +2.15% | mature |
| 40d | +2.55% | +12.56% | mature |